dc.contributor.author | Shah, V | |
dc.contributor.author | Sherborne, AL | |
dc.contributor.author | Johnson, DC | |
dc.contributor.author | Ellis, S | |
dc.contributor.author | Price, A | |
dc.contributor.author | Chowdhury, F | |
dc.contributor.author | Kendall, J | |
dc.contributor.author | Jenner, MW | |
dc.contributor.author | Drayson, MT | |
dc.contributor.author | Owen, RG | |
dc.contributor.author | Gregory, WM | |
dc.contributor.author | Morgan, GJ | |
dc.contributor.author | Davies, FE | |
dc.contributor.author | Cook, G | |
dc.contributor.author | Cairns, DA | |
dc.contributor.author | Houlston, RS | |
dc.contributor.author | Jackson, G | |
dc.contributor.author | Kaiser, MF | |
dc.contributor.author | on behalf of NCRI Haematology Clinical Studies Group, | |
dc.date.accessioned | 2020-04-02T11:47:31Z | |
dc.date.issued | 2020-03-11 | |
dc.identifier.citation | Leukemia, 2020, 34 (11), pp. 3091 - 3096 | |
dc.identifier.issn | 0887-6924 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3574 | |
dc.identifier.eissn | 1476-5551 | |
dc.identifier.doi | 10.1038/s41375-020-0750-z | |
dc.format | Print-Electronic | |
dc.format.extent | 3091 - 3096 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGERNATURE | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | on behalf of NCRI Haematology Clinical Studies Group | |
dc.subject | Humans | |
dc.subject | Multiple Myeloma | |
dc.subject | Chromosome Aberrations | |
dc.subject | Prognosis | |
dc.subject | Stem Cell Transplantation | |
dc.subject | Proportional Hazards Models | |
dc.subject | Gene Expression Profiling | |
dc.subject | Transcriptome | |
dc.subject | Biomarkers, Tumor | |
dc.title | Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-02-06 | |
rioxxterms.versionofrecord | 10.1038/s41375-020-0750-z | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2020-11 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Leukemia | |
pubs.issue | 11 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Cancer Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group | |
pubs.publication-status | Published | |
pubs.volume | 34 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Cancer Genomics | |
icr.researchteam | Myeloma Group | |
dc.contributor.icrauthor | Houlston, Richard | |
dc.contributor.icrauthor | Kaiser, Martin | |